Clinical trials: Over Cancer
Neoplasms
BI 811283 in Various Solid Tumours
The main objective of this trial is to provide safety data in terms of drug-related adverse events (AE) for the recommendation of the dose for further trials in the development of BI 811283.
- Trial name
- NCT00701324
- Testing
- BI 811283
- Where
- 2 sites in Germany
- Volunteers
- 124 people
- Sponsor
- Boehringer Ingelheim
Myasthenia Gravis, Myasthenia Gravis, MuSK
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID)…
- Trial name
- SYNAPSE-MG (NCT06414954)
- Testing
- NMD670
- Where
- 40 sites in United States, Belgium and 8 more
- Volunteers
- 84 people
- Sponsor
- NMD Pharma A/S
Lymphoma, B-cell, Diffuse
Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma
For SyB L-0501RI administered by an intravenous rapid infusion in combination with rituximab, the safety will be investigated in previously untreated patients with low-grade B-cell non-Hodgkin's lymphoma (Lg-B-NHL) or mantle cell…
- Trial name
- NCT03900377
- Testing
- SyB L-0501RI
- Where
- 14 sites in Japan
- Volunteers
- 37 people
- Sponsor
- SymBio Pharmaceuticals
ALK Positive Malignancies
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with…
- Trial name
- NCT02584933
- Testing
- ceritinib
- Where
- 71 sites in United States, Australia and 19 more
- Volunteers
- 233 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasms
Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
This randomized, open-label, crossover study will evaluate participants' preference and healthcare professional (HCP) satisfaction with SC versus IV Herceptin administration in HER2-positive early breast cancer.
- Trial name
- PrefHER (NCT01401166)
- Testing
- Herceptin, Single-Use Injection Device
- Where
- 75 sites in Canada, Denmark and 10 more
- Volunteers
- 488 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator
- Trial name
- NCT01789281
- Testing
- Everolimus, Sandostatin LAR Depot
- Where
- 24 sites in United States, Czechia and 7 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Tuberous Sclerosis Complex
Basimglurant (NOE-101) in Children, Adolescents, and Young Adults With TSC
The study intends to show that basimglurant (NOE-101) provides effective seizure control in children, adolescents and young adults with Tuberous Sclerosis Complex (TSC).
- Trial name
- NCT05059327
- Where
- 27 sites in United States, India and 6 more
- Volunteers
- 61 people
- Sponsor
- Noema Pharma AG
Chronic Pain, Insomnia
The Efficacy of CALPXT96™in Improving Sleep Quality in Patients With Chronic Non-cancer Pain
California Poppy has been traditionally used in Herbal Medicine as an analgesic, mild sedative and/or sleep aid. However there are no human clinical trial data to support its use.
- Trial name
- CALPXT96 (NCT02232256)
- Testing
- CALPXT96
- Where
- Canada
- Sponsor
- 9305-9954 Quebec Inc
Leiomyoma
Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670
Effects of BAY1002670 on bleeding pattern: non-bleeding rate; on endometrium; on ovarian function; return of menstrual bleeding after treatment; safety and tolerability; PK/PD (pharmacokinetic/pharmacodynamic) relationship
- Trial name
- NCT01816815
- Testing
- BAY1002670
- Where
- 6 sites in Belgium, Germany and 1 more
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Bayer
Tumors
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
This is a Phase 1, open-label, randomized, 2-sequence, cross-over, pharmacokinetic (PK) study evaluating the effect of the DPD inhibitory action of CDHP as an S-1 component compared with FT alone on the PK of 5-FU in patients…
- Trial name
- NCT00400023
- Testing
- S-1, FT
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Taiho Oncology, Inc.
Multiple Myeloma, Breast Cancer
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
The primary objective of this study is to investigate the repeat-dose pharmacokinetic (PK) profile of zoledronic acid when administered every 4 weeks versus every 12 weeks, in patients treated with 9-20 infusions of zoledronic…
- Trial name
- NCT00424983
- Testing
- Zoledronic acid
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Acute Promyelocytic Leukemia (APL)
Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
Randomized, Open-Label Study to evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution (SDK001) under Fasting and Fed Conditions, to Compare to IV Arsenic Trioxide
- Trial name
- NCT06882031
- Testing
- Treatment A: Arsenic Trioxide (ATO) Intravenous, Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state, Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state
- Where
- Hong Kong
- Volunteers
- 12 people
- Sponsor
- SDK Therapeutics, Inc.
Gastrointestinal Stromal Tumors
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
The purpose of this study is to collect and assess long-term safety of nilotinib in patients who are on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs study and are benefiting from…
- Trial name
- NCT01863745
- Testing
- nilotinib
- Where
- 11 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
Actinic Keratoses
Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK
Actinic keratosis (AK), also known as solar keratosis, is a common skin condition characterised by abnormal growth of skin cells caused by long-term sun exposure.
- Trial name
- COAKS (NCT05164393)
- Testing
- AVX001
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Coegin Pharma AB
Cancer
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
The purpose of this study is to enable patients, who are currently receiving rogaratinib in a Bayer-sponsored clinical trial (incl. NCT01976741), to continue treatment after their respective study has been closed.
- Trial name
- NCT04125693
- Testing
- Rogaratinib (BAY1163877), Combination drug
- Where
- Switzerland
- Volunteers
- 1 people
- Sponsor
- Bayer
Cancer - Ovarian
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
This study will evaluate the bioavailability between the veliparib tablet formulation to the capsule formulation; and will assess the effect of food on veliparib bioavailability in participants with ovarian cancer.
- Trial name
- NCT03400306
- Testing
- Veliparib, capsule, Veliparib, tablet, Carboplatin
- Sponsor
- AbbVie
Breast Cancer, Breast Neoplasms
Effectiveness of CadAI-B Dx for Decision Support in Breast Ultrasound
This is a retrospective, fully-crossed, multi-reader, multi-case (MRMC) study to evaluate the effectiveness of 'CadAI-B Dx' (CadAI-B) for decision support in breast ultrasound.
- Trial name
- NCT07287111
- Testing
- CadAI-B Dx
- Where
- South Korea
- Volunteers
- 797 people
- Sponsor
- BeamWorks Inc.
Lymphedema of Leg, Lymphedema
A Preference Study of Two Pneumatic Compression Devices for Patients With Lower Limb Lymphedema
This study will aim to undertake a preference evaluation comparing the Aria Health Aria Free™ to a competitor's device by assessing overall satisfaction and preference of the devices individually and in comparison to one another.
- Conditions
- Lymphedema of Leg, Lymphedema, Lymphedema, Secondary, Lymphedema Primary
- Trial name
- NCT05485454
- Testing
- Aria Health Aria Free, A Traditional PCD
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- ResMed
Breast Cancer
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: HR-positive…
- Trial name
- FourLight-3 (NCT06760637)
- Testing
- PF-07220060, letrozole, abemaciclib
- Where
- 460 sites in United States, Argentina and 28 more
- Volunteers
- 1,035 people
- Sponsor
- Pfizer
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 2 to 5 years.
- Trial name
- NCT01596426
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd